Search
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedWF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The Corporation believes the research...
Estazolam
go.drugbank.com/drugs/DB01215ApprovedIllicitInvestigationalA benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
BBT-877
go.drugbank.com/drugs/DB18668InvestigationalBBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis.
Gatipotuzumab
go.drugbank.com/drugs/DB18861InvestigationalGatipotuzumab is under investigation in clinical trial NCT01899599 (Pankomab-gex™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer).
Synonyms: Immunoglobulin g1, anti-(mucin muc1) (human-mus musculus monoclonal pankomab-gex heavy chain), disulfide with human-mus musculus monoclonal pankomab-gex light chain, dimerAlbuvirtide
go.drugbank.com/drugs/DB15166InvestigationalAlbuvirtide is under investigation in clinical trial NCT03719664 (Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects).
ORM-13070 C-11
go.drugbank.com/drugs/DB15324InvestigationalORM-13070 C-11 is under investigation in clinical trial NCT00735774 (Suitability of 11C-ORM-13070 as a PET Tracer).
Butyric Acid
go.drugbank.com/drugs/DB03568InvestigationalA four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.
Ambrosia artemisiifolia pollen
go.drugbank.com/drugs/DB10385ApprovedAmbrosia artemisiifolia pollen is the pollen of the Ambrosia artemisiifolia plant. Ambrosia artemisiifolia pollen is mainly used in allergenic testing.
Anthoxanthum odoratum
go.drugbank.com/drugs/DB14163ApprovedAnthoxanthum odoratum allergenic extract is used in allergenic testing.
CX-051869
go.drugbank.com/drugs/DB31656ApprovedCX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1. It is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.